877271-27-7Relevant academic research and scientific papers
Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus
Zheng, Xiaofan,Hudyma, Thomas W.,Martin, Scott W.,Bergstrom, Carl,Ding, Min,He, Feng,Romine, Jeffrey,Poss, Michael A.,Kadow, John F.,Chang, Chong-Hwan,Wan, John,Witmer, Mark R.,Morin, Paul,Camac, Daniel M.,Sheriff, Steven,Beno, Brett R.,Rigat, Karen L.,Wang, Ying-Kai,Fridell, Robert,Lemm, Julie,Qiu, Dike,Liu, Mengping,Voss, Stacey,Pelosi, Lenore,Roberts, Susan B.,Gao, Min,Knipe, Jay,Gentles, Robert G.
, p. 2925 - 2929 (2011)
Herein, we present initial SAR studies on a series of bridged 2-arylindole-based NS5B inhibitors. The introduction of bridging elements between the indole N1 and the ortho-position of the 2-aryl moiety resulted in conformationally constrained heterocycles
Synthesis of indolo[2,1-a][2]benzazepine and indolo[2,1-a][2]-benzazocine
Ponzi, Simona,Habermann, J?rg,Ferreira, Maria Del Rosario Rico,Narjes, Frank
experimental part, p. 1395 - 1400 (2009/10/21)
The synthesis of functionalised 6,7-dihydro-5H-indolo[ 2,1-a][2]benzazepine and 5,6,7,8-tetrahydroindolo[2,1-a][2]benzazocine from methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate, involving RCM as the key step to generate the tetracyclic indolo[2,1-a][2]benzazepine and indolo[2,1-a][2] benzazocine core structure, is outlined. Georg Thieme Verlag Stuttgart.
Discovery of pentacyclic compounds as potent inhibitors of hepatitis C virus NS5B RNA polymerase
Habermann, J?rg,Capitò, Elena,Ferreira, Maria del Rosario Rico,Koch, Uwe,Narjes, Frank
scheme or table, p. 633 - 638 (2009/08/07)
We report a new series of inhibitors for hepatitis C virus NS5B RNA polymerase containing a constrained pentacyclic scaffold. Our SAR studies led to the identification of hexahydroindolo[2,1-a]pyrrolo[3,2-d][2]benzazepines exposing basic groups. The compo
PENTACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS
-
Page/Page column 24-25, (2008/06/13)
The present invention relates to pentacyclic indole derivatives of formula (I): wherein A, Ar, R1, R2, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.
TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS
-
Page/Page column 53, (2010/11/08)
The present invention relates to tetracyclic indole compounds of formula (I); wherein R1, R2, A, Ar, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.
Inhibitors of HCV replication
-
Page/Page column 39, (2010/10/20)
Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds.
